Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

Benzinga · 1d ago
Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:CNMD) with a Neutral and raises the price target from $39 to $45.